Buccal Cannabinoid Troche Formulation for Precise Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabis-based products for medical use often contain harmful preservatives and stabilizers, and fail to provide effective relief due to sub-therapeutic dosing and variable clinical responses, lacking efficient and reproducible dosage adjustment.
Innovation Solution
A cannabinoid lozenge or troche formulation using polyethylene glycol, gelatin, or pectin as bases, combined with oils and specific ratios of cannabinoids and terpenes, administered buccally or sublingually, avoiding harmful additives and optimizing synergistic effects, with precise dosage adjustment capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabis-based products use traditional oral formulations (capsules, tinctures, edibles), then they are easy to manufacture and administer, but they provide sub-therapeutic dosing and fail to achieve effective relief
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by using a water-soluble base (polyethylene glycol) instead of traditional lipid-based carriers, enabling precise dosing through controlled dissolution rates and improving bioavailability while maintaining manufacturing feasibility
Solution Approach 2:
The patent creates a composite troche formulation combining water-soluble polyethylene glycol base with cannabis extract, creating a new material system that dissolves in the mouth to provide controlled release and improved therapeutic efficacy compared to traditional single-phase formulations
2Stability of the object's composition
If cannabis-based products contain preservatives (BHT, BHA) and stabilizers to extend shelf life, then product stability is improved, but harmful substances and side effects increase
Solution Approach 1:
The patent removes harmful preservatives and stabilizers from the formulation entirely, relying instead on the inherent stability of the water-soluble polyethylene glycol base and controlled manufacturing process to achieve acceptable shelf life without toxic additives
Solution Approach 2:
The patent accepts a shorter shelf life in exchange for eliminating harmful substances, creating a formulation that is safe and effective for its intended use period without requiring long-term preservative systems
3Adaptability or versatility
If cannabis products use fixed dosing formulations, then manufacturing is simplified, but dosage adjustment flexibility is reduced
Solution Approach 1:
The patent divides the troche into multiple equal segments or cuts, allowing the total dose to be divided into smaller adjustable portions while maintaining precise manufacturing of the total amount, thus achieving both dosage flexibility and manufacturing consistency
Data Source
AI summary
A cannabinoid troche including polyethylene glycol (or other base ingredients such as gelatin and/or pectin) and oils of peppermint, ginger, citrus, mango, etc., that is administered buccally and/or sublingually. This dosage form demonstrates an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles. The troches avoid harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. The use of peppermint oil (and others) in the troche shows improved efficacy above and beyond that which is expected or seen without its use. The troches further allow for accurate and reproducible therapeutic effects with ease of dosage adjustments.